Skip to main content
Tag

Alzheimer's disease Archives - BioHealth Innovation

NIA Launches 2027 Start-Up Challenge and Accelerator with $994,000 in Cash Prizes

By News

The National Institute on Aging (NIA), part of the National Institutes of Health, has launched the fourth NIA Start-Up Challenge and Accelerator, offering early-stage innovators a combination of funding, entrepreneurial training, mentorship, and networking to help advance new technologies focused on aging and older adults.

The 2027 Challenge will award up to $994,000 in total cash prizes while providing selected entrepreneurs with hands-on support to move research-driven ideas toward commercialization.

The Challenge is seeking innovative tools, technologies, and interventions that address aging-related diseases and conditions, including Alzheimer’s disease and related dementias. NIA is also looking for solutions that promote healthy aging, help older adults age in the place of their choice, improve care delivery, and reduce the burden on caregivers.

A Focus on Early-Stage Innovators

The program is designed in particular for individuals and teams that are new to entrepreneurship or are still at an early stage of building a company.

Selected finalists will each receive a $24,000 cash prize and participate in a five-month entrepreneurial accelerator featuring mentorship, education, networking, and business development support.

Participants will also receive guidance on navigating NIH funding opportunities, including NIA’s Small Business Innovation Research and Small Business Technology Transfer programs, commonly known as SBIR and STTR.

At the conclusion of the accelerator, participants will pitch their ventures for the opportunity to become one of seven winners, each receiving an additional $70,000 cash prize.

For researchers and innovators who have developed promising science but may have limited experience building a company, raising capital, developing a commercialization strategy, or navigating the NIH small business ecosystem, the Challenge offers an opportunity to build those capabilities alongside experienced mentors.

Important Dates

The Challenge launched September 1, 2026, with submissions opening December 1, 2026.

NIA will host an informational webinar on December 3, 2026, at 1:00 p.m. ET for prospective applicants interested in learning more about the program, application process, and expectations.

Applications must be submitted by January 15, 2027.

Mentors Wanted

NIA is also seeking experienced professionals in research, technology translation, entrepreneurship, investment, commercialization, and related fields to serve as mentors for the next accelerator cohort.

Mentors have the opportunity to work directly with emerging entrepreneurs as they develop their technologies, business strategies, and commercialization plans.

BioHealth Innovation encourages entrepreneurs, researchers, and aspiring founders across the BioHealth Capital Region who are developing technologies related to aging and healthy longevity to explore this opportunity.

Learn more about the 2027 NIA Start-Up Challenge and Accelerator and register for the December 3 informational webinar through the National Institutes of Health. https://www.nih.gov/challenges/2027-nia-start-challenge-accelerator

Measuring Brain Health in Real Time: Matt Adams on BrainScope’s AI-Enabled Platform on BioTalk

By BioTalk with Rich Bendis Podcast, News

In this episode of BioTalk with Rich Bendis, Matt Adams, Chief Executive Officer of BrainScope, joins the conversation to discuss how the Rockville-based company is working to bring objective brain function measurement into real-world clinical care.

Matt shares how BrainScope is using EEG-based technology and artificial intelligence to help decode brain electrical activity and provide clinicians, patients, and care teams with simple, actionable information. He explains why objective data is especially important in brain health, where many assessments can still be subjective, difficult to scale, or dependent on more expensive infrastructure.

Listen via your favorite podcast platform:
Apple: https://apple.co/45FA0RX
Spotify: https://bit.ly/3Sbowm5
iHeart Podcasts: https://ihr.fm/4qBHsqX
Amazon Podcasts: https://amzn.to/4qvM95m
YouTube Podcasts (Audio): https://bit.ly/4gpBEgN
TuneIn: https://bit.ly/4xnE2L0

The conversation also looks at BrainScope’s evolution since winning the BioHealth Capital Region Crab Trap Competition in 2020. Matt discusses how the company has moved from a point-of-care EEG technology focused on traumatic brain injury into a broader AI-enabled brain health platform with potential applications across concussion, brain bleeds, dementia, Alzheimer’s disease, and other neurological conditions.

Rich and Matt also discuss BrainScope’s FDA-cleared technology, its growing clinical and regulatory foundation, and how the company is using machine learning, deep learning, and a large EEG database to expand what can be measured in brain health. Matt highlights the company’s work in Alzheimer’s prediction, including data suggesting the potential to identify risk years before typical clinical diagnosis, as well as the opportunity to support longitudinal monitoring and improved CNS trial design.

The episode also looks ahead to BrainScope’s next phase, including expanded disease applications, partnerships with clinicians and sports medicine organizations, potential use in clinical trials, global market opportunities, and the company’s continued growth in the BioHealth Capital Region.

Editing and post-production work for this episode was provided by The Podcast Consultant.

Matt Adams brings more than 25 years of global healthcare leadership experience developing, commercializing, and scaling medical device, biotechnology, diagnostic product, and service businesses. He currently serves as Chief Executive Officer of BrainScope, a tech-enabled AI software platform focused on brain health. Before joining BrainScope, Matt was President of Invio Automation, a global life science-focused process automation provider. He previously served as Vice President and General Manager of Cerevention, a neuro startup that developed and commercialized platforms to diagnose and treat hemorrhagic stroke and other diseases of the central nervous system. He has also held executive roles at Rebiotix, Cirle, and American Medical Systems. Matt received his eMBA from the University of Minnesota, a Master of Science in Biomedical Engineering from the University of Minnesota, and a Bachelor of Science in Mechanical Engineering from the University of Alaska.

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.